Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ART plus dual long-acting HIV bNAbs vs ART plus placebo in primary HIV-1 infection
2024-516150-22-00Phase 2Authorised
- Sponsor
- ANRS
- Start
- Oct 2024
- Modality
- Anti-infectious Disease mAbs → Neutralizing Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics, Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Teropavimab and zinlirvimab in human immunodeficiency virus infection (HIV) (2 arms), sponsored by ANRS. Primary endpoint: Proportion of participants with plasma HIV-1 RNA below 400 copies/mL at 24 weeks following ATI in the confirmed absence of ART (post-treatment controllers). Planned start Oct 2024; status: authorised.
02
Drugs
Teropavimabzinlirvimab
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2024-516150-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516150-22-00.